What dog longevity research can tell us about healthy aging

Anyone who has loved an older dog recognizes the small changes: a slower walk, less interest in play, a familiar routine that suddenly becomes confusing. Helping dogs remain comfortable, alert and active is a worthwhile goal in itself. It also brings researchers closer to a question that concerns all of us: can we change how we age, rather than only treat the illnesses that appear along the way?

Dogs are particularly interesting because they share our homes, surroundings and many age-related health problems. They age more quickly than people, allowing researchers to study changes over a shorter period. The Dog Aging Project brings that everyday connection into science. [1]

Why we follow this field closely

We are proud to support this work through Longevity Tech Fund, whose portfolio includes Animal Biosciences and Genflow. Their approaches are different: Animal Biosciences is developing products for healthier aging in companion animals, while Genflow is investigating SIRT6 gene therapy. Both reflect our interest in turning advances in aging biology into more years of good health. [15] [16]

LeapYears: an encouraging finding for the aging brain

Older dogs can develop problems with memory, attention and familiar routines. In a trial involving 70 senior dogs with mild to moderate cognitive difficulties, researchers tested LY-D6/2, the combination associated with LeapYears. It brings together a compound intended to help clear senescent cells—cells that have stopped dividing but remain active—and a precursor of NAD+, a molecule involved in cellular energy and repair. [2] [3]

Owners of dogs receiving the full amount reported the greatest improvement in cognitive scores over three months. This is encouraging because owners see their dogs in everyday situations that a short clinic visit cannot fully capture. Neither owners nor researchers knew which dogs received the supplement or a placebo. [2]

The study also measured movement with activity monitors and tested cognitive skills in the clinic. Those measures did not show a clear treatment advantage. That does not erase the improvement owners reported; it means the benefit was clearer in one kind of assessment than in others. Longer studies can help establish how noticeable and lasting that improvement is. Lifespan was not measured. [2]

A later study from the same group explored why questionnaires and clinic tests can tell different stories. Extra attention and participation in a study can themselves influence how dogs behave and how owners rate them. The questionnaire used in the original trial was more resistant to this effect than another commonly used scale. Together, the studies show the value of combining observations at home with other ways of assessing an older dog's health. [4]

Genflow: helping cells cope with aging

Genflow is taking a different route. Its research focuses on SIRT6, a protein involved in DNA maintenance and other processes linked to aging. The aim is to give cells genetic instructions that could strengthen these protective functions.

In its SLAB study in older beagles, Genflow has reported encouraging changes in physical function and survival during the initial treatment period. Its February 12, 2026 announcement described early improvements, and an April 8 update reported that improvements persisted after treatment stopped. These are early company-reported findings from a small study. [6]

In September, the company also reported a reduction in an age estimate based on chemical markings on DNA. Often called an aging clock, this kind of measurement can help researchers understand a treatment's biological effects. It is an encouraging part of the picture, alongside how well the animals move and function. Following the dogs over time will show whether these changes translate into a lasting improvement in health and lifespan. [5]

Loyal: can a medicine add healthy years?

Loyal's development program asks that question directly. Its experimental medicine LOY-002 is intended for older dogs, and the STAY study is following more than 1,300 dogs through participating veterinary practices. Dogs receive the medicine or a placebo, and researchers track lifespan, health and quality of life over several years. [10]

The company has also made progress through the US animal-drug review process. It announced acceptance of the safety section of the LOY-002 application in January 2026, following an earlier effectiveness milestone. In September it announced a separate milestone for LOY-003, a candidate for large and giant-breed dogs. At the September 22 review date, LOY-002's conditional approval and availability were still pending. [7] [8] [17]

Conditional approval is a veterinary pathway that can allow a medicine onto the market while further evidence of effectiveness is collected. Safety and manufacturing standards still apply. For owners, the practical point is to check the actual approval and label with a veterinarian when considering a treatment. [9]

Rapamycin: moving from small studies to a longer test

Rapamycin affects a cellular pathway involved in growth and the response to nutrients. It has attracted attention in aging research, but finding the right use in companion animals requires its own studies.

One small trial followed 17 dogs given rapamycin or a placebo. Some owners reported positive behavioral changes, but the study did not establish the hoped-for improvement in heart function. Its small size leaves room for uncertainty about more modest effects. [12]

Follow-up also identified a substantial rise in blood fats in one treated dog, even though the dog appeared well. The abnormality resolved after treatment ended. This single case cannot tell us how common the problem might be, but it shows why veterinary monitoring matters when exploring a medicine's potential benefits. [13]

The larger TRIAD study is designed to provide a more direct answer about lifespan. Its published plan calls for 580 companion dogs, a year of treatment and several years of follow-up. Studies on this scale can help reveal whether a promising biological idea becomes a meaningful benefit in everyday life. [14] [18]

What this could mean for people

For us at Healthy Longevity Clinic, the appeal of this research is its focus on living well: maintaining movement, engagement and resilience as we age. Healthy Longevity Clinic’s approach to evaluating evidence connects new scientific ideas with the health outcomes people care about.

Dog studies can help identify useful biological targets and reveal effects worth testing in people. They cannot tell us directly which treatment will work for a person. Differences between species, formulations and health conditions still need to be worked through in human research.

The most exciting prospect is a future in which aging pets remain active and engaged for longer, and what we learn helps shape better human medicine. That future is being built through several routes at once: supplements, gene therapy and carefully studied medicines. Their progress deserves attention, with each discovery understood for what it adds.

If you are considering a product for your dog

Start with a conversation about what you want to improve: comfort, mobility, memory or another specific concern. Ask your veterinarian whether the product has been studied in dogs like yours and how you will judge its benefit. The exact formulation matters, and any treatment needs an appropriate plan for monitoring. A veterinary regimen should not be copied for personal use.